EP0835099B1 - Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes - Google Patents

Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes Download PDF

Info

Publication number
EP0835099B1
EP0835099B1 EP96917085A EP96917085A EP0835099B1 EP 0835099 B1 EP0835099 B1 EP 0835099B1 EP 96917085 A EP96917085 A EP 96917085A EP 96917085 A EP96917085 A EP 96917085A EP 0835099 B1 EP0835099 B1 EP 0835099B1
Authority
EP
European Patent Office
Prior art keywords
nucleic acid
liposomes
lipid film
factor
dna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96917085A
Other languages
German (de)
English (en)
Other versions
EP0835099A1 (fr
EP0835099A4 (fr
Inventor
Alain Thierry
Anatoly Dritschilo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Georgetown University
Original Assignee
Georgetown University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Georgetown University filed Critical Georgetown University
Publication of EP0835099A1 publication Critical patent/EP0835099A1/fr
Publication of EP0835099A4 publication Critical patent/EP0835099A4/fr
Application granted granted Critical
Publication of EP0835099B1 publication Critical patent/EP0835099B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/88—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using amphiphile liposome vesicle
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes

Definitions

  • transfecting polynucleotides into target cells include conventional means such as calcium phosphate and polycation-mediated transfection, as well as protoplast fusion, viral and retroviral infection, microinjection and electroporation.
  • Another method recently investigated for delivery of polynucleotides into cells involves the administration of liposomally-encapsulated nucleic acids.
  • Such methods originated in the early 1980's when Papahadjopoulos et al . disclosed the encapsulation of biologically-active materials, such as nucleic acids and proteins, in liposomes. These liposomes were then used for delivery of the biologically active materials to target cells. See, e.g., U.S. Patent No. 4,241,046; U.S. Patent No. 4,235,871; U.S. Patent No. 4,394,448. See also, Lasic et al ., Science 267:1275 (1995).
  • pH-sensitive liposomes also provide for enhanced delivery of targeted nucleic acids into cells.
  • U.S. Patent No. 4,789,633 and Huang et al., Proc. Nat'l. Acad. Sci. USA 87 :7851 (1987) disclose pH-sensitive DNA containing liposomes which fuse with cell membranes at a pH below 7, thereby facilitating introduction of the desired DNA. While such liposomes enable improved delivery of foreign DNA's, they are still quite inefficient, generally because of poor entrapment efficiency. This poor entrapment efficiency means both that large quantities of DNA are wasted in preparing the liposomes, and that large quantities of liposomes must be used to achieve delivery of a given amount of DNA to cells.
  • Another method for achieving delivery of DNA containing liposomes involves the administration of complexes of DNA with cationic lipids.
  • U.S. Patent No. 5,227,170 teaches encapsulation of oligonucleotides in cationic lipid complexes which further comprise a divalent cation solution containing the desired oligonucleotides and which have an osmolarity less than that of the internal aqueous phase. See also , Felgner et al., Proc. Nat'l. Acad. Sci. USA, 84 :7413 (1987).
  • liposomes Due to their cationic character, these liposomes can bind to serum proteins, thereby leading to inactivation of the oligonucleotides contained therein. Also, osmotic-dependent liposomes are known in the literature, i.e. , as disclosed by U.S. Patent No. 5,049,392.
  • U.S. Patent No. 4,532,089 teaches a method for preparing giant liposomes.
  • U.S. Patent No. 4,529,561 teaches a method for preparing liposomes in desired size ranges.
  • U.S. Patent No. 5,223,263 teaches liponucleotide containing liposomes and the use thereof in delivery of the liponucleotides to desired cells.
  • nucleic acids are suitable only for encapsulation of small nucleotides, e.g., oligonucleotides.
  • This is disadvantageous since expression of heterologous gene products in cells often requires the introduction of much larger DNA sequences that include not only coding regions, but also other cis-acting controls for regulating gene expression, such as promoter and enhancer sequences, operator sequences and the like, as well as a ribosome binding site, an initiation codon and transcription termination and polyadenylation signals.
  • Buffer regions, origins of replication for extra-chromosomal replication, and flanking regions with homology to a target site for targeted chromosomal insertion by homologous recombination may also be included.
  • a method for encapsulating in liposomes nucleic acids ranging from about 1 to 20 kB and, preferably, from about 5 to about 18 kB, comprising the steps of (i) incubating a hydrated lipid film for an effective time at reduced temperature, where the hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film; (ii) adding a minimum effective amount of phosphate buffered saline solution to the hydrated lipid film and vortexing for a time sufficient to generate liposomes and to swell the liposomes; and (iii) vortexing the resulting swelled liposomes.
  • the method may also further comprise the step of (iv) removing unencapsulated nucleic acid from said liposomes by washing said liposomes. The washing may be achieved
  • the lipid film comprises at least one lipid selected from the group consisting of dimyristoyl-diglycerol, phosphatidylethanolamine, phosphatidylcholine, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, gangliosides, cerebrosides, cholesterol, tocopherol, and retinol.
  • lipid selected from the group consisting of dimyristoyl-diglycerol, phosphatidylethanolamine, phosphatidylcholine, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, gangliosides, cerebrosides, cholesterol, tocop
  • the lipid film comprises dimyristoyldiglycerol, phosphatidylethanolamine and cholesterol, in a relative molar ratio of about 5:5:7 respectively.
  • the nucleic acid solution has a concentration of 1-5 mg/ml, and the nucleic acid solution is added to the dried lipid film in a ratio of less than or equal to about 1.6 ⁇ l per mg of lipid.
  • the effective time for the incubating step is preferably at least 12 hours, and the time for forming and swelling the liposomes is at least 30 minutes.
  • the size of the nucleic acid is preferably from about 1 kB to about 25 kB, or more preferably from about 5 kB to about 18 kB.
  • a method for transfecting cells comprising contacting a cell with an effective amount of swelled nucleic acid-containing liposomes, wherein the liposomes are prepared as described above.
  • the nucleic acid is preferably a plasmid, a phagemid, or a cosmid.
  • a liposome comprising a high molecular weight nucleic acid, produced by the method described above.
  • the nucleic acid has a size of at least 2 kB, and at least 25% of the liposomes contain the nucleic acid.
  • the nucleic acid has a size of at least 5 kB, and at least 10% of the liposomes contain the nucleic acid.
  • the liposome contains a high molecular weight DNA encoding an antisense RNA, a ribozyme, or a therapeutic protein.
  • a method for preparing a liposome-encapsulated nucleic acid comprising the steps of (i) incubating a hydrated lipid film for about 2 hours at about 4°C, wherein the hydrated lipid film is formed by addition of a concentrated aqueous solution of a high molecular weight nucleic acid to a dried lipid film in a ratio of less than or equal to about 1.6 ⁇ l of DNA solution per mg of lipid; ( ii) adding a phosphate buffered saline solution to the hydrated lipid film in a ratio of less than or equal to about 1.6 ⁇ l per mg of lipid, and vortexing for a time sufficient to generate liposomes and to swell the liposomes; and (iii) vortexing the resulting swelled liposomes, whereby at least 25% of said liposomes contain the nucleic acid.
  • the high molecular weight DNA encodes
  • a liposome prepared by the methods described above, wherein the therapeutic protein is selected from the group consisting of platelet-derived growth factor, epidermal growth factor, interleukins 1-14, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, tumor necrosis factor, leukemia inhibitory factor, amphiregulin, angiogenin, betacellulin, calcitonin, ciliary neurotrophic factor, brain-derived neurotrophic factor, neurotrophins 3 and 4, nerve growth factor, colony stimulating factor-1, endothelial cell growth factor, erythropoietin, acidic and basic, fibroblast growth factor, hepatocyte growth factor, heparin binding EGF-like growth factor, insulin, insulin-like growth factors I and II, interferons ⁇ , ⁇ , and ⁇ , keratinocyte growth factor, macrophage inflammatory protein ⁇ and ⁇ , midkine, oncostatin M, RAN
  • the present invention provides an improved method for the encapsulation of high molecular weight nucleic acids in liposomes, wherein a higher nucleic acid entrapment efficiency is achieved than can be achieved by conventional methods for encapsulating nucleic acids in liposomes.
  • entrapment efficiency is defined as the percentage of the initial amount of the nucleic acid used which becomes encapsulated in the resulting liposomes.
  • This improved method also provides liposomal compositions in which a greater proportion of the liposomes actually contain the desired nucleic acids, than can be achieved with conventional methods for encapsulating nucleic acids in liposomes. Additionally, each liposome comprises a higher nucleic acid content, on average, than liposomes generated by conventional techniques.
  • the high encapsulation efficiency which is generally at least 25%, and usually 50% based upon the initial amount of nucleic acid, but which may be as high or even higher than 90%, reduces cost since it requires less nucleic acid than conventional liposome encapsulation processes.
  • high entrapment efficiency improves the performance quality of the nucleic acid-containing liposomes because (i) a greater portion of the liposomes contain nucleic acid and (ii) the average nucleic acid content is higher than in liposomes generated by conventional methods. This translates into improved delivery of nucleic acids to target cells and, accordingly, there is a greater probability that a nucleic acid will be delivered to any given target cell. Because each nucleic acid delivered may not achieve stable transfection, a higher delivery rate improves the chance that a cell will be produced which expresses the desired product.
  • nucleic acid or “polynucleotide” as used herein are considered interchangeable unless otherwise indicated, and encompass DNA, RNA or a mixture of DNA and RNA.
  • Nucleic acids according to the present invention may also include any strand structure, e.g. , single-, double- or triple-stranded polynucleotide structures or mixtures thereof. Also, the nucleic acids may comprise linear or circular structures, e . g ., plasmids, phagemids, cosmids, etc .
  • high molecular weight polynucleotide refers to a polynucleotide molecule that comprises at least one coding sequence that can be transcribed when the polynucleotide is introduced into a host cell. This transcription can produce an mRNA molecule that can then be translated to produce a polypeptide or protein, or it can produce an antisense RNA molecule. Transcription of the coding sequence of the HMW polynucleotide is preferably under the control of cis -acting regulatory elements, such as enhancer sequences, operator sequences and the like, and the polynucleotide also contains a ribosome binding site, an initiation codon and transcription termination and polyadenylation signals.
  • HMW polynucleotides as used herein is, therefore, generally understood to mean polynucleotides that contain such regulatory elements.
  • the HMW polynucleotide may also contain other elements such as origins of replication as are commonly found on polynucleotides used for transfection.
  • the present invention provides for the efficient encapsulation of large vectors, including those which contain sequences that permit stable, episomal maintenance and those which encode multigene cassettes. This is significant, in the case of episomal constructs, because integration of the desired nucleic acid into the host cell's genome may have a negative impact on the transfection process. For multigene cassettes, it also is important as coordinate regulation of the encoded genes can be more easily achieved.
  • the nucleic acids which may be encapsulated according to the present method may range in size from as small as about 500 bases to about 50 kilobases.
  • the encapsulated nucleic acids will comprise DNA's ranging from about 1.0 to 25 kB and, preferably, from about 5 to about 18 kB.
  • the nucleic acids which may be encapsulated according to the present method may comprise sense or antisense polynucleotides.
  • antisense oligonucleotides may be encapsulated which selectively inhibit the expression of target DNA's.
  • antisense oligonucleotides may be encapsulated which are complementary to viral sequences and utilized for antiviral treatments, e.g. , hepatitis, AIDS viral infection, papillomavirus infection, etc .
  • antisense oligonucleotides for genetic therapy has been reported in the literature. See Stein and Chang, Science 261 : 1004 (1993).
  • ribozymal RNA's may be encapsulated and used to study gene expression or for genetic therapy.
  • the encapsulated nucleic acids will comprise an episomal element, e.g. , a plasmid which contains one or more genes which are to be expressed in target cells.
  • An episomal element containing an origin of replication that is recognized by the replication functions of the host cell will be stably maintained in the cell as an extrachromosomal element, thereby allowing stable expression of genes encoded on the element. In general, these genes will cause the target cell to produce a heterologous expression product, or acquire an altered phenotype. If the episomal element does not contain an origin of replication that is recognized by the host cell, the expression product will be produced only transiently.
  • Another utility for the subject liposomal encapsulated nucleic acids will comprise producing cells or animals which express a defective gene or genes. Thereby, the resulting cells or animals may be used as in vitro or in vivo models for assessing the efficacy of potential therapeutic agents.
  • a further utility for the liposomally encapsulated nucleic acids of the invention is for gene therapy, that is for introducing into cells DNA constructs that encode a therapeutic product.
  • the therapeutic product can be, for example, an antisense RNA or ribozyme RNA molecule, or it can be a therapeutic protein.
  • a "therapeutic protein” as used herein refers to a peptide, polypeptide, or protein that confers a therapeutic benefit to a host when administered to the host, or when it is expressed in cells of the host.
  • the gene therapy can be in vivo, in which the liposomally encapsulated DNA constructs are introduced directly into a host animal, preferably a human, or can be ex vivo, in which isolated cells are first transfected with the liposomally encapsulated DNA constructs, and are then reintroduced into a host animal.
  • Ex vivo gene therapy in humans is described in U.S. patent 5,399,346, which is hereby incorporated by reference in its entirety. See also Tolstoshev, Annu. Rev. Pharmacol. Toxicol . 33:573-96 (1993), for a general review of gene therapy, which is also incorporated herein by reference in its entirety.
  • the subject nucleic acid containing liposomes will, in general, be made by a method comprising:
  • step (iv) there will be an intervening step between step (iv) and step (v) wherein additional phosphate buffered saline solution is added and the mixture is again vortexed.
  • step (vi) the unencapsulated (free) nucleic acids typically will be removed. This may be effected, for example, by washing the liposomes repeatedly while centrifuging in a phosphate buffered saline solution.
  • lipid in general, about 20 ⁇ mole (about 0.64 mg) of lipid is dried under reduced pressure (30mm Hg) in a 40 mm 2 surface of a round-bottom glass flask or tube. The resulting dry lipid film is hydrated with about 1.4 ⁇ l of aqueous solution containing DNA to be encapsulated.
  • a container having a mean surface area of about 10 to 200 mm 2 is used, under a reduced pressure of about 1 to 50mm Hg, and a hydration volume of about 0.7 to 2 ⁇ l.
  • Step (i) typically will be effected by forming a lipid film using any lipid or mixture of suitable lipids which are evaporated under a vacuum.
  • the lipid mixture used to make this lipid film will comprise any lipid or mixture of lipids which provides for suitable nucleic acid entrapment efficiency.
  • lipids suitable for use in the invention include, e.g ., known vesicle or liposome forming compounds such as phosphatidylcholine, both naturally occurring and synthetically prepared, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, phosphatidyl ethanolamine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, gangliosides, and cerebrosides such as soybean phospholipids.
  • known vesicle or liposome forming compounds such as phosphatidylcholine, both naturally occurring and synthetically prepared, phosphatidic acid, lysophosphatidylcholine, phosphatidylserine, phosphatidyl ethanolamine, sphingolipids, phosphatidylglycerol, sphingomyelin, cardiolipin, glycolipids, ganglio
  • Suitable lipids include steroids, cholesterol, aliphatic amines such as long chain aliphatic amines and carboxylic acids, long chain sulfates and phosphates, diacetyl phosphates, butylated hydroxy toluene, tocopherol, retinol and isoprenoid compounds which may confer desired properties to the formed liposomes.
  • synthetic phospholipids containing either altered aliphatic portions such as hydroxyl groups, branched carbon chains, cyclo derivatives, aromatic derivatives, ethers, amides, polyunsaturated derivatives, halogenated derivatives or altered hydrophilic portions containing carbohydrate, glycol, phosphate, phosphamide, quaternary amines, sulfate, sulfonyl, carboxy, amine, sulphydryl, imidazole groups and combinations of such groups can be either substituted or intermixed with the above-mentioned lipids which may be used in the present invention.
  • Lipids suitable for use in preparing liposomes are well known in the literature, and are described, e.g., in U.S. Patent No. 4,201,767; U.S. Patent No. 4,235,877; U.S. Patent No. 4,241,046; U.S. Patent No. 4,261,975; and U.S. Patent No. 4,394,448, all of which are incorporated by reference in their entireties.
  • the present invention embraces the use of any lipid or combination which provides the desired encapsulation efficiency which, in general, will be at least about 25%, relative to the initial amount of nucleic acid used for encapsulation.
  • the encapsulation efficiency will be preferably at least 50%, more preferably 70%, and still more preferably will be in the range from about 70% to about 90%
  • Preferred lipids include dimyristoyl phosphatidyl glycerol, cardiolipin, phosphatidyl choline, phosphatidyl glycerol, sphingomyelin, and cholesterol.
  • the lipids used to make the lipid film comprise a mixture of dimyristoyldiglycerol, phosphatidylethanolamine and cholesterol. Most preferably, the molar ratio of these lipids is about 5:5:7 of dimyristoyldiglycerol, phosphatidylethanolamine and cholesterol, respectively.
  • Step (ii), the hydration step in general, comprises the addition of an effective amount of a nucleic acid-containing aqueous solution to a dried lipid film.
  • this solution will comprise a highly concentrated, aqueous, nucleic acid solution and, more preferably, a concentrated DNA containing solution.
  • a preferred concentration range for the DNA solution is from about 1 mg/ml to about 5 mg/ml, but concentrations outside this range may also be used, for example from about 0.01 mg/ml to about 20 mg/ml, or up until the DNA solution is saturated.
  • the solution comprises plasmids in an aqueous solution at a concentration of about 1-2 mg/ml. This concentrated nucleic acid solution is added to the dry lipid film in an amount sufficient to provide hydration and to achieve the desired amount of nucleic acid encapsulation.
  • a 2 mg/ml DNA plasmid solution was utilized, at 1.6 ⁇ l solution/mg lipid, to facilitate hydration. This amount may be varied as needed.
  • a suitable amount of the nucleic acid-containing solution will vary from about 1.7 to 17 ⁇ g of DNA per mg of lipid if utilizing a nucleic acid solution having a concentration of about 1-5 mg/ml of DNA.
  • the nucleic acid contained in this solution may comprise DNA, RNA or a mixture thereof, and may comprise linear or circular structures.
  • the encapsulated nucleic acids may be single or multi-stranded and may comprise sense or antisense nucleic acid sequences.
  • the nucleic acids will comprise DNA constructs having a size ranging from about 5 to about 18 kilobases.
  • such DNA constructs will contain a gene or genes which are to be expressed in the targeted cells.
  • the DNA construct also preferably will contain suitable regulatory sequences which provide for the expression of these genes, in addition to sequences that provide for these DNA constructs to autonomously replicate in target cells if necessary, and also suitable selectable markers, e.g., antibiotic resistance markers. In general, these genes will be expressed under the control of regulatable promoters.
  • the DNA constructs will contain a gene or genes which produce a therapeutic or valuable gene product.
  • gene products include, but are not limited to, therapeutic lymphokines, cytokines, hormones, cell adhesion molecules, enzymes or enzyme inhibitors, receptors, ion channels, transcription factors, protein kinases, protein phosphatases, and cellular antigens for generating an immune response in a host.
  • the DNA constructs will contain suicide genes, tumor suppressor genes, genes encoding antisense RNAs, or genes that induce or prevent cellular apoptosis.
  • lymphokines and cytokines that can be encoded by the liposomally-encapsulated DNA constructs of the invention include platelet-derived growth factor, epidermal growth factor, interleukins 1-14, granulocyte colony stimulating factor, granulocyte-macrophage colony stimulating factor, tumor necrosis factor, leukemia inhibitory factor, amphiregulin, angiogenin, betacellulin, calcitonin, ciliary neurotrophic factor, brain-derived neurotrophic factor, neurotrophins 3 and 4, nerve growth factor, colony stimulating factor-1, endothelial cell growth factor, erythropoietin, acidic and basic, fibroblast growth factor, hepatocyte growth factor, heparin binding EGF-like growth factor, insulin, insulin-like growth factors I and II, interferons ⁇ , ⁇ , and ⁇ , keratinocyte growth factor, macrophage inflammatory protein ⁇ and ⁇ , midkine, oncostatin M, RANTES, stem cell factor
  • cell adhesion molecules include integrins, cadherins, selectins, and adhesion molecules of the immunoglobulin superfamily, such as VCAM, ICAM, PECAM, and NCAM.
  • tumor suppressor genes include p53, DCC, Rb, and MTS1. Those of skill in the art will recognize that other genes can also be used in the invention.
  • the DNA construct will contain regulatory elements that can control replication of the construct within the cell, as well as transcription and translation of genes encoded on the construct.
  • regulatory elements For use in in vivo gene therapy it is sometimes useful for these regulatory elements to be tissue specific.
  • tissue-specific promoter or "tissue-specific transcriptional regulatory sequence” indicates a transcriptional regulatory sequence, promoter and / or enhancer that is induced selectively or at a higher level in cells of the target tissue than in other cells.
  • tumor cell-specific promoters include promoters that are induced selectively or at a higher level in a particular cell type or a tumor cell.
  • Tissue specific promoters are known in the art. Examples include: the alpha-actin promoter (Shani, Mol. Cell.
  • Step (iii) of the subject method comprises incubating the hydrated lipid film for about 12 to 24 hours at a reduced temperature, for example at about 4°C.
  • Step (iv) will in general comprise the addition of a minimum effective amount of a phosphate buffered saline solution followed by vortexing.
  • This minimum effective amount of the added phosphate buffer solution will be less than about 1.6 ⁇ l/mg of lipid, and preferably will range from about 0.5 to 1.5 ⁇ l/mg lipid.
  • 1.4 ⁇ l of phosphate buffered saline solution was added per mg of the hydrated lipid.
  • the initial vortexing will be followed by another step wherein additional phosphate buffered saline solution is added followed by vigorous vortexing.
  • additional phosphate buffered saline solution is added followed by vigorous vortexing.
  • This may be effected by the addition of a second phosphate buffered saline solution in an amount less than about 1.6 ⁇ l/mg of lipid, and preferably from about 0.5 to about 1.5 ⁇ l/mg lipid.
  • Step (v) comprises incubating the mixture obtained from step (iv) for a time sufficient to permit swelling and, thereafter, generation of liposomes.
  • this will comprise incubating the mixture at ambient temperature for at least about 30 minutes, and preferably at least about 2 hours.
  • the swelling time was 2 hours.
  • Additional PBS solution (8 ⁇ l/mg of lipid) may optionally be added at this point to dilute the liposome solution.
  • Step (vi) comprises homogenization and resuspension of the swelled liposome composition, usually by vortexing.
  • this step is conveniently and efficiently carried out by sonication of the liposome mixture.
  • This procedure is not suitable, however, for liposomes containing larger DNA constructs, which degrade rapidly under sonication conditions. It has been found, unexpectedly, that thorough mixing, homogenization and resuspension can be achieved by vortexing the liposome mixture.
  • the composition preferably will be treated to remove the free nucleic acids. This may be effected by any suitable method which does not adversely affect the liposomes, for example, by washing the liposomes in a suitable solution, e.g. , phosphate buffered saline, followed by centrifugation.
  • a suitable solution e.g. , phosphate buffered saline
  • Nucleic acid-containing liposomes produced in this manner may be used immediately or may be stored under favorable conditions, e.g., at about 4°C. Liposomes according to the present invention are stable for up to three weeks.
  • the encapsulation efficiency may be ascertained by known methods. For example, a DNA sample containing radiolabeled plasmid DNA constructs can be employed. This permits determination of the relative amounts of liposome-contained and free radioactivity.
  • the subject method reliably provides for nucleic acid entrapment efficiencies ranging from at least 25 to 50%, and more typically about 70 to 90% based upon the initial amount of nucleic acid contained in the sample, e.g. , a DNA plasmid containing sample.
  • the liposomes may be used for both in vitro or in vivo transfection of nucleic acids into targeted cells.
  • the targeted cells can be any cell whose cellular membrane is comprised of a lipid bilayer, and in general will comprise eukaryotic cells, and preferably mammalian cells, more preferably murine or human cells.
  • the subject liposomes are to be administered in vivo , it may be preferable to conjugate these liposomes to a moiety which provides for the liposome to bind to targeted cells.
  • targeting moieties will include antibodies, or ligands which selectively bind to the targeted cells.
  • Methods for conjugating liposomes to targeting moieties, e.g. , antibodies are well known in the art and are discussed, supra.
  • the subject liposomes may be conjugated to an antiviral antibody if the liposomes contain an antiviral construct, e.g ., a nucleic acid which encodes a gene product which renders transfected cells susceptible to a particular drug.
  • a suitable amount of the subject liposomes will be added to a cell culture medium containing the targeted cells.
  • a suitable amount of the liposome composition may range from about 0.12 to 1.2 mg of liposome per 10 6 cells, or from about 0.1 to about 10 ⁇ g of encapsulated DNA per 10 6 cells. Those of skill in the art will realize, however, that this amount can vary, depending upon factors such as the lability of the particular targeted cell, its resistance to transfection, whether the liposomes contain smaller or larger nucleic acids, the activity of the particular gene, and the desired level of gene expression.
  • the resulting liposomally-transfected cells may be used for various applications.
  • the cells may be used to express a polypeptide encoded by the incorporated nucleic acids, e . g ., a desired mammalian gene product.
  • the incorporated nucleic acids result in the cells expressing a particular genetic defect, the cells may be used as models for studying the efficacy of proposed therapies for the particular genetic defect.
  • nucleic acid-containing liposomes are to be used in vivo, they are administered to a host in need of genetic therapy.
  • Another variation on in vivo use is for the generation of genetic defects, e.g., transgenic or "knock-out" mice which are useful in the study of disease.
  • An example of genetic therapy in a patient is when a DNA construct encoding human leukocyte antigen B7 (HLAB7) is encapsulated in a liposome as described supra and injected directly into the tumor lesions of a patient suffering from cutaneous melanoma, as described in Nabel et al., Proc. Natl. Acad. Sci . 90:11307 (1993), which is hereby incorporated by reference in its entirety.
  • the HLAB7 stimulates the host immune response against the melanoma cells.
  • an in vivo liposomal dosage will range from about 0.2 to 20 mg/kg of body weight, and preferably from about 2 mg to 10 mg/kg of body weight.
  • the amount will, of course, depend on the particular genetic defect, the type of nucleic acid encapsulated, the desired level of gene expression, the amount of nucleic acid contained in the liposomes, and other factors as discussed supra.
  • a particular advantage of the present invention is that it provides for the delivery of episomal elements to targeted cells, e.g ., DNA plasmids.
  • the liposomes will be conjugated to a targeting moiety, e.g ., an antibody to enhance delivery, when the desired target is an in vivo one, e.g. , a tumor. This will avoid some of the problems which occur via integration of heterologous nucleic acids into normal host cell genomes.
  • Liposome compositions according to the present invention may be administered with additional substances, e.g ., pharmaceutical carriers and excipients.
  • additional substances e.g ., pharmaceutical carriers and excipients.
  • suitable carriers or excipients are described in REMINGTON'S PHARMACEUTICAL SCIENCES: DRUG RECEPTORS AND RECEPTOR THEORY, (18th ed.), Mack Publishing Co., Easton PA (1990).
  • the choice of carrier, diluent, excipient, etc. will depend upon the desired mode of delivery.
  • the liposomal compositions of the invention can be administered by any route currently known for delivering polynucleotide molecules to cells, including, but not limited to intravenous or intramuscular injection, transdermally as a component of an ointment or cream, intratracheally, intranasally, or orally by aerosol or by drip, rectally, etc.
  • the liposomes will be administered by injection.
  • liposomes according to the present invention may be administered in vivo in combination with other medicaments suitable for use in treating a particular disorder.
  • the liposomes may contain a "suicide gene" which renders targeted cells susceptible to a particular drug, it may be desirable to coadminister liposomes in with the drug.
  • the drug may be, but need not be, liposomally encapsulated.
  • the efficiency of in vivo or in vitro transfection may be measured by standard methods. See Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, Cold Spring Harbor Laboratory, Cold Spring Harbor, New York (1989).
  • the expression of genes encoded on a liposomally encapsulated DNA construct transfected into cells in vitro can be studied by Northern blotting or RNA PCR to measure production of RNA transcripts, and by Western blotting, immunoprecipitation, and in situ immunohistochemistry to detect and measure protein production. Integration of the DNA into the host cell chromosome can be determined by PCR or by Southern blotting. The same methods are used to determine whether tissue treated in vivo contains transfected genes, or is expressing gene products of the transfected genes. This is preferably carried out on a biopsy sample of the tissue of interest.
  • Liposome-encapsulated DNA was prepared by thin lipid hydration using a highly concentrated DNA solution. Specifically, dimyristoylphosphatidyldiglycerol, phosphatidylethanolamine, and cholesterol were mixed at a 5:5:7 molar ratio in a round-bottom flask, with a total weight of 6.4 mg. A thin lipid film was formed by rotary evaporation under vacuum. The resultant dry lipid film was then hydrated by adding 10 ⁇ l of a 2 mg/ml solution of 32 P-labeled plasmid DNA. The hydrated lipid film was then incubated overnight at 4°C.
  • PBS phosphate buffer saline
  • the encapsulation efficiency was then determined by counting the radioactivity comprised in an aliquot of a liposomal DNA preparation.
  • the entrapment rate was found to be 70-90% based upon the initial counts. Moreover, this result was reliably reproducible in additional trials.
  • Squamous carcinoma SCC 35 cells were transfected with plasmids pSV40 neo and pRSVcat which contain the neomycin resistance gene and the chloramphenicol acyltransferase gene, respectively. These plasmids were chosen to allow measurement of the efficiencies of transient and stable transfection of cells transfected by various transfection methods.
  • pSV40 neo contains a gene for neomycin resistance, thereby allowing transfected cells that express the gene product to survive in culture in medium containing neomycin.
  • the only cells that survive are ones that have stably integrated the neo gene into their chromosomes.
  • pRSVcat (Promega Corp., Madison, WI) contains a gene encoding chloramphenicol acyltransferase. The level of transient expression of the cat gene in cells that are transfected with pRSV cat was measured with a standard CAT assay.
  • Table 1 compares the results obtained after transfecting SCC 35 cells with pSV40 neo and pRSV cat using the minimum volume entrapment (MVE) liposomal transfection method of the present invention, with the results obtained with DEAE-dextran under standard conditions, with calcium phosphate under standard condition, and with a commercially available cationic lipid reagent (Lipofectin, Life Technologies, Gaithersburg, MD) under conditions recommended by the manufacturer.
  • MVE minimum volume entrapment
  • nucleic acids encapsulated in liposomes according to the present invention provide for greatly enhanced transfection efficiencies relative to other available techniques, e.g. , DEAE-dextran, calcium phosphate and LipofectinTM reagent mediated transfection. While not wishing to be bound by any theory of mechanism of action, the present inventors believe that the enhanced transfection efficiencies seen with the method of the present invention are attributable to its high encapsulation efficiency, which provides a liposome population in which a very high percentage of the liposomes contain encapsulated nucleic acids.
  • Plasmid DNA (18kb) was nick translated with 35 S under standard conditions. See Sambrook et al., MOLECULAR CLONING: A LABORATORY MANUAL, Second Edition, (Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989). This DNA was then encapsulated in liposomes as described in Example 1.
  • the liposomes were constituted from dimyristoyl phosphatidylglycerol, phosphatidylethanolamine and cholesterol in a 5:5:7 ratio, as described in Example 1.
  • This liposomal solution was added to a culture of SCC35 squamous cell carcinoma cells seeded in microchamber glass slides, at a final liposome concentration of 1 ⁇ M.
  • the cells were then incubated for 24 h, after which they were washed and then subjected to emulsion autoradiography. This showed a dense array of black dots, corresponding to the presence of radioactively labeled plasmid DNA, in the intracellular compartment and surrounding the cell surface. These results demonstrated that liposomal DNA was effectively taken up by the cells, and penetrated.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Dispersion Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Wood Science & Technology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)

Claims (15)

  1. Procédé pour la préparation d'un acide nucléique encapsulé dans un liposome, comprenant les étapes suivantes :
    (i) l'incubation d'un film lipidique hydraté pendant une période de temps efficace à température réduite, dans laquelle ledit film lipidique est formé par addition d'une solution aqueuse concentrée d'un acide nucléique à poids moléculaire élevé sur un film lipidique séché, dans laquelle la taille dudit acide nucléique est d'au moins 2 kB et dans laquelle ladite solution d'acide nucléique a une concentration de 1 à 5 mg/ml et est ajoutée audit film lipidique séché dans un rapport inférieur ou égal à environ 1,6 µl par mg de lipide;
    (ii) l'addition d'une quantité minimale efficace d'une solution physiologique tamponnée au phosphate au film lipidique hydraté et l'application d'un mouvement tourbillonnant pendant une période de temps suffisante pour générer des liposomes et gonfler lesdits liposomes; et
    (iii) l'application d'un mouvement tourbillonnant aux liposomes gonflés obtenus.
  2. Procédé selon la revendication 1, dans lequel ledit film lipidique comprend au moins un lipide choisi dans le groupe constitué du dimyristoyl-diglycérol, de la phosphatidyléthanolamine, de la phosphatidylcholine, de l'acide phosphatidique, de la lysophosphatidylcholine, de la phosphatidylsérine, des sphingolipides, du phosphatidylglycérol, de la sphingomyéline, de la cardiolipine, des glycolipides, des gangliosides, des cérébrosides, du cholestérol, du tocophérol et du rétinol.
  3. Procédé selon la revendication 2, dans lequel ledit film lipidique comprend du dimyristoyldiglycérol, de la phosphatidyléthanolamine et du cholestérol dans un rapport molaire relatif d'environ 5:5:7, respectivement.
  4. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite période de temps efficace pour l'étape d'incubation est d'au moins 12 heures.
  5. Procédé selon l'une quelconque des revendications précédentes, dans lequel ladite période de temps de formation et de gonflement desdits liposomes est d'au moins 30 minutes.
  6. Procédé selon l'une quelconque des revendications précédentes, dans lequel la taille dudit acide nucléique est d'environ 2 kB à environ 20 kB, de préférence d'environ 5 kB à environ 18 kB.
  7. Procédé selon l'une quelconque des revendications précédentes, dans lequel le procédé comprend en outre l'étape (iv) d'élimination de l'acide nucléique non encapsulé desdits liposomes par lavage desdits liposomes, de préférence en les lavant par centrifugation.
  8. Procédé selon l'une quelconque des revendications précédentes, dans lequel ledit acide nucléique est un plasmide, un phagémide ou un cosmide.
  9. Procédé pour transfecter des cellules, comprenant la mise en contact d'une cellule avec une quantité efficace de liposomes gonflés contenant un acide nucléique, dans lequel lesdits liposomes sont préparés par le procédé selon l'une quelconque des revendications 1 à 8.
  10. Liposome comprenant un acide nucléique à poids moléculaire élevé produit par le procédé selon l'une quelconque des revendications 1 à 8.
  11. Liposome selon la revendication 10, dans lequel ledit ADN à poids moléculaire élevé code pour un ARN antisens, un ribozyme ou une protéine thérapeutique.
  12. Liposome selon la revendication 11, dans lequel ladite protéine thérapeutique est choisie dans le groupe constitué d'un facteur de croissance dérivé de plaquettes, d'un facteur de croissance épidermique, des interleukines 1 à 14, du facteur de stimulation de développement de colonies de granulocytes G-CSF, du facteur de stimulation de développement de colonies de granulocytes/macrophages GM-CSF, du facteur nécrosant les tumeurs, du facteur inhibiteur de leucémie, de l'amphiréguline, de l'angiogénine, de la bêtacelluline, de la calcitonine, du facteur neurotrophique ciliaire, du facteur neurotrophique dérivé du cerveau, des neurotrophines 3 et 4, du facteur de croissance nerveuse, du facteur-1 de stimulation du développement de colonies, du facteur de croissance de cellules endothéliales, de l'érythropoïétine, du facteur de croissance de fibroblastes acides et basiques, du facteur de croissance d'hépatocytes, du facteur de croissance analogue à l'EGF de fixation d'héparine, de l'insuline, des facteurs de croissance I et II analogues à l'insuline, des interférons α, β et χ, du facteur de croissance de kératinocytes, de la protéine inflammatoire de macrophage α et β, de la midkine, de l'oncostatine M, de RANTES, du facteur de cellules souches, de facteurs de croissance de transformation α et β et du facteur de croissance endothéliale vasculaire et/ou dans lequel ledit ADN à poids moléculaire élevé code en outre pour un promoteur spécifique au tissu lié en activité audit ARN antisens, audit ribozyme ou à ladite protéine thérapeutique.
  13. Préparation de liposomes comprenant un acide nucléique ayant une taille d'au moins 2 kB, dans laquelle au moins 25% desdits liposomes contiennent ledit acide nucléique.
  14. Préparation de liposomes comprenant un acide nucléique ayant une taille d'au moins 5 kB, dans laquelle au moins 10% desdits liposomes contiennent ledit acide nucléique.
  15. Procédé de préparation d'un acide nucléique encapsulé dans un liposome comprenant les étapes suivantes :
    (i) l'incubation d'un film lipidique hydraté pendant environ 2 h à température ambiante, dans laquelle ledit film lipidique hydraté est formé par addition d'une solution aqueuse concentrée d'un acide nucléique à poids moléculaire élevé sur un film lipidique séché dans un rapport inférieur ou égal à environ 1,6 µl de solution d'ADN par mg de lipide, dans laquelle l'acide nucléique a une taille d'au moins 2 kB et dans laquelle ladite solution d'acide nucléique a une concentration de 1 à 5 mg/ml;
    (ii) l'addition d'une solution physiologique tamponnée au phosphate au film lipidique hydraté dans un rapport supérieur ou égal à environ 1,6 µl par mg de lipide et l'application d'un mouvement tourbillonnant pendant une période de temps suffisante pour générer des liposomes et gonfler lesdits liposomes; et
    (iii) l'application d'un mouvement tourbillonnant aux liposomes gonflés obtenus de sorte qu'au moins 25% dudit acide nucléique soient incorporés auxdits liposomes.
EP96917085A 1995-06-07 1996-06-06 Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes Expired - Lifetime EP0835099B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/483,090 US5756122A (en) 1995-06-07 1995-06-07 Liposomally encapsulated nucleic acids having high entrapment efficiencies, method of manufacturer and use thereof for transfection of targeted cells
US483090 1995-06-07
PCT/US1996/008619 WO1996040062A1 (fr) 1995-06-07 1996-06-06 Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes

Publications (3)

Publication Number Publication Date
EP0835099A1 EP0835099A1 (fr) 1998-04-15
EP0835099A4 EP0835099A4 (fr) 2000-11-08
EP0835099B1 true EP0835099B1 (fr) 2004-10-20

Family

ID=23918616

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96917085A Expired - Lifetime EP0835099B1 (fr) 1995-06-07 1996-06-06 Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes

Country Status (7)

Country Link
US (1) US5756122A (fr)
EP (1) EP0835099B1 (fr)
AT (1) ATE279912T1 (fr)
AU (1) AU700376B2 (fr)
CA (1) CA2223637A1 (fr)
DE (1) DE69633669T2 (fr)
WO (1) WO1996040062A1 (fr)

Families Citing this family (159)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6168778B1 (en) 1990-06-11 2001-01-02 Nexstar Pharmaceuticals, Inc. Vascular endothelial growth factor (VEGF) Nucleic Acid Ligand Complexes
US5855911A (en) * 1995-08-29 1999-01-05 Board Of Regents, The University Of Texas System Liposomal phosphodiester, phosphorothioate, and P-ethoxy oligonucleotides
CN100478033C (zh) * 1995-08-29 2009-04-15 安增生摩祺株式会社 含有hgf基因的药物
US6977244B2 (en) * 1996-10-04 2005-12-20 Board Of Regents, The University Of Texas Systems Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US6426335B1 (en) 1997-10-17 2002-07-30 Gilead Sciences, Inc. Vascular endothelial growth factor (VEGF) nucleic acid ligand complexes
US20030229040A1 (en) * 1997-03-21 2003-12-11 Georgetown University Cationic liposomal delivery system and therapeutic use thereof
US6126965A (en) 1997-03-21 2000-10-03 Georgetown University School Of Medicine Liposomes containing oligonucleotides
US7262173B2 (en) * 1997-03-21 2007-08-28 Georgetown University Chemosensitizing with liposomes containing oligonucleotides
US6528271B1 (en) 1997-06-05 2003-03-04 Duke University Inhibition of βarrestin mediated effects prolongs and potentiates opioid receptor-mediated analgesia
DE69838521T2 (de) 1997-07-07 2008-05-21 Medical Research Council Methode zur Erhöhung der Konzentration von Nucleinsäuremolekülen
US7285288B1 (en) 1997-10-03 2007-10-23 Board Of Regents, The University Of Texas System Inhibition of Bcl-2 protein expression by liposomal antisense oligodeoxynucleotides
US7704962B1 (en) 1997-10-03 2010-04-27 Board Of Regents, The University Of Texas System Small oligonucleotides with anti-tumor activity
US6083923A (en) * 1997-10-31 2000-07-04 Isis Pharmaceuticals Inc. Liposomal oligonucleotide compositions for modulating RAS gene expression
US7098192B2 (en) 1999-04-08 2006-08-29 Isis Pharmaceuticals, Inc. Antisense oligonucleotide modulation of STAT3 expression
US6277893B1 (en) 1999-05-10 2001-08-21 National Starch & Chemical Co. Investment Holding Corporation Polysaccharide and dimethicone copolyol as emulsifier for cosmetic compositions
WO2001013986A1 (fr) * 1999-08-25 2001-03-01 Georgetown University Systeme d'administration therapeutique comprenant des grains creux, de preference metalliques, et utilisation
AU775965B2 (en) 1999-10-08 2004-08-19 Anges Mg, Inc. Gene therapy for cardiomyopathy
ES2313907T3 (es) * 1999-10-29 2009-03-16 Anges Mg, Inc. Terapia genica para la isquemia diabetica.
WO2001041739A2 (fr) * 1999-12-13 2001-06-14 Lipoxen Technologies Limited Liposomes
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US6261840B1 (en) 2000-01-18 2001-07-17 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
CA2425092A1 (fr) * 2000-10-06 2002-04-11 Michael F. Holick Regulation de la proliferation et de la differenciation cellulaire au moyen d'une application localisee de molecules d'acide nucleique
US7279324B2 (en) 2001-01-23 2007-10-09 Duke University Nucleic acid encoding G-protein coupled receptor with modified DRY motif
WO2002059337A1 (fr) * 2001-01-26 2002-08-01 Georgetown University School Of Medicine Gène anti-apoptotique scc-s2 et ses utilisations diagnostiques et thérapeutiques
CA2451643C (fr) 2001-06-21 2012-11-13 Isis Pharmaceuticals, Inc. Modulation anti-sens de l'expression de la superoxyde dismutase 1 soluble
AUPR621501A0 (en) 2001-07-06 2001-08-02 Commonwealth Scientific And Industrial Research Organisation Delivery of ds rna
US6964950B2 (en) 2001-07-25 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of C-reactive protein expression
US20030096772A1 (en) 2001-07-30 2003-05-22 Crooke Rosanne M. Antisense modulation of acyl CoA cholesterol acyltransferase-2 expression
US7407943B2 (en) 2001-08-01 2008-08-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein B expression
US7227014B2 (en) 2001-08-07 2007-06-05 Isis Pharmaceuticals, Inc. Antisense modulation of apolipoprotein (a) expression
NZ585001A (en) 2001-10-09 2011-08-26 Isis Pharmaceuticals Inc Antisense modulation of insulin-like growth factor binding protein 5 expression
US6750019B2 (en) 2001-10-09 2004-06-15 Isis Pharmaceuticals, Inc. Antisense modulation of insulin-like growth factor binding protein 5 expression
US6965025B2 (en) 2001-12-10 2005-11-15 Isis Pharmaceuticals, Inc. Antisense modulation of connective tissue growth factor expression
EP1380289A1 (fr) * 2002-07-10 2004-01-14 Denis Bron Système de delivrance pour les agents pharmaceutiques
EA008940B1 (ru) 2002-09-13 2007-10-26 Репликор, Инк. Антивирусные олигонуклеотиды, не связанные с комплементарностью последовательностей
EP2272958A1 (fr) 2002-09-26 2011-01-12 ISIS Pharmaceuticals, Inc. Modulation de l'expression de la boîte Forkhead O1A
PT2336318E (pt) 2002-11-13 2013-06-12 Genzyme Corp Modulação anti-sentido da expressão de apolipoproteína b
AU2003294281B2 (en) 2002-11-13 2010-05-20 Kastle Therapeutics, Llc Antisense modulation of apolipoprotein B expression
US8980310B2 (en) * 2002-12-31 2015-03-17 Bharat Serums and Vaccines, Ltd. Non-pegylated long-circulating liposomes
US20060078893A1 (en) 2004-10-12 2006-04-13 Medical Research Council Compartmentalised combinatorial chemistry by microfluidic control
GB0307403D0 (en) 2003-03-31 2003-05-07 Medical Res Council Selection by compartmentalised screening
GB0307428D0 (en) 2003-03-31 2003-05-07 Medical Res Council Compartmentalised combinatorial chemistry
US7825235B2 (en) 2003-08-18 2010-11-02 Isis Pharmaceuticals, Inc. Modulation of diacylglycerol acyltransferase 2 expression
EP1547581A1 (fr) * 2003-12-23 2005-06-29 Vectron Therapeutics AG Vaccin liposomal pour le traitement de maladies malignes humaines et hematologiques
CA2559161C (fr) 2004-03-12 2013-06-11 Alnylam Pharmaceuticals, Inc. Agents arni ciblant le facteur de croissance de l'endothelium vasculaire (vegf)
US20050221339A1 (en) 2004-03-31 2005-10-06 Medical Research Council Harvard University Compartmentalised screening by microfluidic control
US7968287B2 (en) 2004-10-08 2011-06-28 Medical Research Council Harvard University In vitro evolution in microfluidic systems
US20060211004A1 (en) 2005-02-15 2006-09-21 Ilsley Diane D Methods and compositions for determining non-specific cytotoxicity of a transfection agent
US7700567B2 (en) 2005-09-29 2010-04-20 Supergen, Inc. Oligonucleotide analogues incorporating 5-aza-cytosine therein
WO2007053696A2 (fr) 2005-11-01 2007-05-10 Alnylam Pharmaceuticals, Inc. Inhibition de la replication du virus de la grippe par interference arn
EP2395012B8 (fr) 2005-11-02 2018-06-06 Arbutus Biopharma Corporation Molécules d'ARNsi modifiées et leurs utilisations
US20100137163A1 (en) 2006-01-11 2010-06-03 Link Darren R Microfluidic Devices and Methods of Use in The Formation and Control of Nanoreactors
US7718629B2 (en) 2006-03-31 2010-05-18 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of Eg5 gene
JP4812874B2 (ja) 2006-04-28 2011-11-09 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｊｃウイルス遺伝子の発現を抑制するための組成物および方法
US9562837B2 (en) 2006-05-11 2017-02-07 Raindance Technologies, Inc. Systems for handling microfludic droplets
JP2010506136A (ja) 2006-05-11 2010-02-25 レインダンス テクノロジーズ， インコーポレイテッド 微小流体デバイス
AU2007253803B2 (en) 2006-05-19 2012-05-24 Alnylam Pharmaceuticals, Inc. RNAi modulation of Aha and therapeutic uses thereof
EP2018443A4 (fr) 2006-05-22 2009-11-11 Alnylam Pharmaceuticals Inc Compositions et méthodes inhibant l'expression du gène ikk-b
US9012390B2 (en) 2006-08-07 2015-04-21 Raindance Technologies, Inc. Fluorocarbon emulsion stabilizing surfactants
WO2008086807A2 (fr) 2007-01-19 2008-07-24 Exiqon A/S Apport cellulaire médié d'oligonucléotides de lna
US8772046B2 (en) 2007-02-06 2014-07-08 Brandeis University Manipulation of fluids and reactions in microfluidic systems
WO2008121604A2 (fr) 2007-03-29 2008-10-09 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour inhiber l'expression d'un gène à partir du virus ébola
US8592221B2 (en) 2007-04-19 2013-11-26 Brandeis University Manipulation of fluids, fluid components and reactions in microfluidic systems
AR066984A1 (es) 2007-06-15 2009-09-23 Novartis Ag Inhibicion de la expresion de la subunidad alfa del canal epitelial de sodio (enac) por medio de arni (arn de interferencia)
EP2848688A1 (fr) 2007-12-10 2015-03-18 Alnylam Pharmaceuticals, Inc. Compositions et procédés d'inhibition d'expression du gène codant pour le facteur VII
ES2535419T3 (es) 2007-12-27 2015-05-11 Protiva Biotherapeutics Inc. Silenciamiento de expresión de quinasa tipo polo usando ARN interferente
KR101397407B1 (ko) 2008-03-05 2014-06-19 알닐람 파마슈티칼스 인코포레이티드 Ｅｇ5 및 ＶＥＧＦ 유전자의 발현을 억제하기 위한 조성물 및 방법
EP2281041B1 (fr) 2008-04-15 2014-07-02 Protiva Biotherapeutics Inc. Réduction au silence de l'expression du gène csn5 au moyen d'arn interférant
US20110076296A1 (en) 2008-04-25 2011-03-31 Innate Pharma S.A. TLR3 Agonist Compositions
EP2315629B1 (fr) 2008-07-18 2021-12-15 Bio-Rad Laboratories, Inc. Bibliothèque de gouttelettes
US12038438B2 (en) 2008-07-18 2024-07-16 Bio-Rad Laboratories, Inc. Enzyme quantification
CA2733262C (fr) 2008-08-25 2019-12-10 Excaliard Pharmaceuticals Inc. Oligonucleotides antissens diriges contre le facteur de croissance des tissus conjonctifs et utilisation de ceux-ci
EP3208337A1 (fr) 2008-09-02 2017-08-23 Alnylam Pharmaceuticals, Inc. Compositions d'inhibition combiné d'expression du mutant egfr et il-6
ES2740129T3 (es) 2008-09-25 2020-02-05 Alnylam Pharmaceuticals Inc Composiciones formuladas en lípidos y métodos de inhibición de la expresión del gen de suero amiloide A
CA2739895C (fr) 2008-10-20 2018-09-25 Alnylam Pharmaceuticals, Inc. Compositions et procedes pour inhiber l'expression de la transthyretine
DK2370112T3 (en) * 2008-11-24 2017-07-24 Bonus Cellora Ltd IMPLANTABLE LIPOSOM INHIBITED MATRIX COMPOSITION AND APPLICATIONS THEREOF
US8324368B2 (en) 2008-12-10 2012-12-04 Alnylam Pharmaceuticals, Inc. GNAQ targeted dsRNA compositions and methods for inhibiting expression
WO2010099341A1 (fr) 2009-02-26 2010-09-02 Alnylam Pharmaceuticals, Inc. Composition et procédés d'inhibition de l'expression du gène mig-12
AU2010223967B2 (en) 2009-03-12 2015-07-30 Alnylam Pharmaceuticals, Inc. Lipid formulated compositions and methods for inhibiting expression of Eg5 and VEGF genes
EP2411148B1 (fr) 2009-03-23 2018-02-21 Raindance Technologies, Inc. Manipulation de gouttelettes microfluidiques
WO2011020023A2 (fr) 2009-08-14 2011-02-17 Alnylam Pharmaceuticals, Inc. Compositions formulées dans des lipides et procédés pour inhiber l’expression d’un gène du virus ebola
US10520500B2 (en) 2009-10-09 2019-12-31 Abdeslam El Harrak Labelled silica-based nanomaterial with enhanced properties and uses thereof
WO2011046983A2 (fr) 2009-10-12 2011-04-21 Smith Holdings, Llc Procédés et compositions de modulation de l'expression génique en utilisant des médicaments à base d'oligonucléotides administrés in vivo ou in vitro
US10837883B2 (en) 2009-12-23 2020-11-17 Bio-Rad Laboratories, Inc. Microfluidic systems and methods for reducing the exchange of molecules between droplets
EP3392349A1 (fr) 2010-02-12 2018-10-24 Raindance Technologies, Inc. Analyse numérique d'analytes
US10351905B2 (en) 2010-02-12 2019-07-16 Bio-Rad Laboratories, Inc. Digital analyte analysis
US9366632B2 (en) 2010-02-12 2016-06-14 Raindance Technologies, Inc. Digital analyte analysis
US9399797B2 (en) 2010-02-12 2016-07-26 Raindance Technologies, Inc. Digital analyte analysis
ES2893199T3 (es) 2010-03-29 2022-02-08 Alnylam Pharmaceuticals Inc Terapia de ARNbc para amiloidosis ocular relacionada con transtiretina (TTR)
CA2792561C (fr) 2010-04-06 2021-10-26 Alnylam Pharmaceuticals, Inc. Compositions et procedes permettant d'inhiber l'expression du gene cd274/pd-l1
EP3456827A3 (fr) 2010-06-02 2019-05-08 Alnylam Pharmaceuticals, Inc. Compositions et procédés permettant de traiter la fibrose du foie
CA2802994A1 (fr) 2010-06-17 2011-12-22 The United States Of America As Represented By The Secretary, National I Nstitutes Of Health Compositions et procedes pour traiter des affections inflammatoires
EP3447155A1 (fr) 2010-09-30 2019-02-27 Raindance Technologies, Inc. Dosages en sandwich dans des gouttelettes
CN103370054A (zh) 2010-11-09 2013-10-23 阿尔尼拉姆医药品有限公司 用于抑制Eg5和VEGF基因的表达的脂质配制的组合物和方法
DK2638149T3 (da) 2010-11-12 2019-08-12 Univ Georgetown Immortalisering af epitelceller og fremgangsmåder til anvendelse
WO2012078967A2 (fr) 2010-12-10 2012-06-14 Alnylam Pharmaceuticals, Inc. Compositions et procédés pour l'augmentation de la production d'érythropoïétine (epo)
US9127275B2 (en) 2010-12-10 2015-09-08 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of klf-1 and bcl11a genes
ES2729956T3 (es) 2011-02-02 2019-11-07 Excaliard Pharmaceuticals Inc Compuestos antisentido dirigidos al factor de crecimiento de tejido conectivo (ctgf) para su uso en un procedimiento de tratamiento de queloides o cicatrices hipertróficas
CA2826594C (fr) 2011-02-03 2019-09-17 The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services Vaccins multivalents pour le virus de la rage et des filovirus
EP3412778A1 (fr) 2011-02-11 2018-12-12 Raindance Technologies, Inc. Procédés permettant de former des gouttelettes mélangées
EP2675819B1 (fr) 2011-02-18 2020-04-08 Bio-Rad Laboratories, Inc. Compositions et méthodes de marquage moléculaire
SG10201602369PA (en) 2011-03-29 2016-05-30 Alnylam Pharmaceuticals Inc Double-Stranded RNA (dsRNA) For Inhibiting Expression Of TMPRSS6
WO2012138453A1 (fr) 2011-04-03 2012-10-11 The General Hospital Corporation Expression protéique efficace in vivo à l'aide d'arn modifié (mod-arn)
US8841071B2 (en) 2011-06-02 2014-09-23 Raindance Technologies, Inc. Sample multiplexing
EP2714892B1 (fr) 2011-06-02 2018-02-21 President and Fellows of Harvard College Procédés et utilisations associées à des systemes de culture tissulaire ex vivo
EP3216872B1 (fr) 2011-06-02 2020-04-01 Bio-Rad Laboratories, Inc. Quantification d'enzyme
US9315813B2 (en) 2011-06-21 2016-04-19 Alnylam Pharmaceuticals, Inc Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes
EP2723865B1 (fr) 2011-06-21 2019-03-27 Alnylam Pharmaceuticals, Inc. PROCÉDÉS DE DÉTERMINATION DE L'ACTIVITÉ DU RNAi CHEZ UN SUJET
EP2723351B1 (fr) 2011-06-21 2018-02-14 Alnylam Pharmaceuticals, Inc. Compositions et procédés d'inhibition de l'expression de gènes de protéine c (proc)
EP3597750B1 (fr) 2011-06-23 2022-05-04 Alnylam Pharmaceuticals, Inc. Arnsi de serpina1 :compositions de matière et procédés de traitement
CN103765212A (zh) 2011-06-27 2014-04-30 杰克逊实验室 治疗癌症和自体免疫性疾病的方法和组合物
US8658430B2 (en) 2011-07-20 2014-02-25 Raindance Technologies, Inc. Manipulating droplet size
EP2739735A2 (fr) 2011-08-01 2014-06-11 Alnylam Pharmaceuticals, Inc. Procédé permettant d'améliorer le taux de succès des greffes de cellules souches hématopoïétiques
JP2014533953A (ja) 2011-11-17 2014-12-18 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 治療用ｒｎａスイッチ組成物及び使用方法
US9035039B2 (en) 2011-12-22 2015-05-19 Protiva Biotherapeutics, Inc. Compositions and methods for silencing SMAD4
US9133461B2 (en) 2012-04-10 2015-09-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the ALAS1 gene
KR101839864B1 (ko) 2012-09-21 2018-03-20 인텐시티 쎄라퓨틱스, 인코포레이티드 암을 치료하는 방법
WO2014130922A1 (fr) 2013-02-25 2014-08-28 Trustees Of Boston University Compositions et procédés pour le traitement d'infections fongiques
EP2978446B1 (fr) 2013-03-27 2020-03-04 The General Hospital Corporation Anticorps anti-cd33 pour le traitement de la maladie d'alzheimer
EP2994167B1 (fr) 2013-05-06 2020-05-06 Alnylam Pharmaceuticals, Inc. Dosages et méthodes pour administrer des molécules d'acides nucléiques à formulation lipidique
CA2925107A1 (fr) 2013-10-02 2015-04-09 Alnylam Pharmaceuticals, Inc. Compositions et methodes d'inhibition de l'expression du gene lect2
TN2016000114A1 (en) 2013-10-04 2017-07-05 Alnylam Pharmaceuticals Inc Compositions and methods for inhibiting expression of the alas1 gene.
US11901041B2 (en) 2013-10-04 2024-02-13 Bio-Rad Laboratories, Inc. Digital analysis of nucleic acid modification
US9944977B2 (en) 2013-12-12 2018-04-17 Raindance Technologies, Inc. Distinguishing rare variations in a nucleic acid sequence from a sample
JP2017500865A (ja) 2013-12-19 2017-01-12 ノバルティス アーゲー レプチンｍＲＮＡの組成物および製剤
US11193176B2 (en) 2013-12-31 2021-12-07 Bio-Rad Laboratories, Inc. Method for detecting and quantifying latent retroviral RNA species
WO2016033424A1 (fr) 2014-08-29 2016-03-03 Genzyme Corporation Méthodes de prévention et de traitement d'évènements indésirables cardiovasculaires majeurs à l'aide de composés modulant l'apolipoprotéine b
BR112017006679A2 (pt) 2014-10-02 2017-12-26 Protiva Biotherapeutics Inc moléculas, composição, partícula, composição farmacêutica, métodos para silenciar a expressão de um gene, usos de uma partícula, métodos para melhorar um ou mais sintomas, métodos para tratar uma infecção, usos de uma composição, método para inibir a replicação do vírus da hepatite d
TW201702218A (zh) 2014-12-12 2017-01-16 美國杰克森實驗室 關於治療癌症、自體免疫疾病及神經退化性疾病之組合物及方法
JP2018504380A (ja) 2014-12-18 2018-02-15 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． Ｒｅｖｅｒｓｉｒ（商標）化合物
US11400139B2 (en) 2015-01-20 2022-08-02 The Children's Medical Center Corporation Anti-NET compounds for treating and preventing fibrosis and for facilitating wound healing
CA2982180A1 (fr) 2015-04-09 2016-10-13 Ambika Bumb Systemes et procedes d'imagerie utilisant des nanodiamants fluorescents
US20180245074A1 (en) 2015-06-04 2018-08-30 Protiva Biotherapeutics, Inc. Treating hepatitis b virus infection using crispr
WO2017004538A1 (fr) 2015-07-02 2017-01-05 Otsuka Pharmaceutical Co., Ltd. Compositions pharmaceutiques lyophilisées
CA2989970A1 (fr) 2015-07-17 2017-01-26 Alnylam Pharmaceuticals, Inc. Conjugues constitues d'une entite unique a cibles multiples
WO2017019891A2 (fr) 2015-07-29 2017-02-02 Protiva Biotherapeutics, Inc. Compositions et méthodes de silençage de l'expression du gène du virus de l'hépatite b
US10647981B1 (en) 2015-09-08 2020-05-12 Bio-Rad Laboratories, Inc. Nucleic acid library generation methods and compositions
WO2017048843A1 (fr) 2015-09-14 2017-03-23 Alnylam Pharmaceuticals, Inc. Compositions et méthodes permettant d'inhiber l'expression du gène alas1
SG11201806868TA (en) 2016-02-25 2018-09-27 Applied Biological Laboratories Inc Compositions and methods for protecting against airborne pathogens and irritants
US20170360815A1 (en) 2016-02-25 2017-12-21 Applied Biological Laboratories, Inc. Compositions and methods for protecting against airborne pathogens and irritants
US11041170B2 (en) 2016-04-04 2021-06-22 Thomas Jefferson University Multivalent vaccines for rabies virus and coronaviruses
US10188749B2 (en) 2016-04-14 2019-01-29 Fred Hutchinson Cancer Research Center Compositions and methods to program therapeutic cells using targeted nucleic acid nanocarriers
WO2018129270A1 (fr) 2017-01-05 2018-07-12 Fred Hutchinson Cancer Research Center Systèmes et procédés pour améliorer l'efficacité d'un vaccin
CA3061752A1 (fr) 2017-07-06 2019-01-10 Arrowhead Pharmaceuticals, Inc. Agents arni d'inhibition d'expression de gene alpha-enac et methodes d'utilisation
AU2018310857A1 (en) 2017-08-03 2020-02-13 Otsuka Pharmaceutical Co., Ltd. Drug compound and purification methods thereof
BR112020022294A2 (pt) 2018-05-04 2021-02-23 Tollys composição e uso de uma composição
US11987792B2 (en) 2018-08-16 2024-05-21 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the LECT2 gene
JP2022513159A (ja) 2018-11-29 2022-02-07 フラッグシップ パイオニアリング イノベーションズ ブイ， インコーポレイテッド Ｒｎａを調節する方法
GB201910299D0 (en) 2019-07-18 2019-09-04 Aouadi Myriam Medical uses, methods and uses
CN114616331A (zh) 2019-09-03 2022-06-10 阿尔尼拉姆医药品有限公司 抑制lect2基因表达的组合物和方法
WO2021067747A1 (fr) 2019-10-04 2021-04-08 Alnylam Pharmaceuticals, Inc. Compositions et méthodes pour le silençage de l'expression génique de l'ugt1a1
US20230040920A1 (en) 2019-11-01 2023-02-09 Alnylam Pharmaceuticals, Inc. Compositions and methods for silencing dnajb1-prkaca fusion gene expression
JP2023514190A (ja) 2020-02-10 2023-04-05 アルナイラム ファーマシューティカルズ， インコーポレイテッド Ｖｅｇｆ－ａ発現をサイレンシングするための組成物および方法
WO2021202443A2 (fr) 2020-03-30 2021-10-07 Alnylam Pharmaceucticals, Inc. Compositions et procédés de silençage de l'expression du gène dnajc15
WO2021207167A1 (fr) 2020-04-06 2021-10-14 Alnylam Pharmaceuticals, Inc. Compositions et méthodes pour le silençage de l'expression de myoc
BR112022020227A2 (pt) 2020-04-07 2022-11-22 Alnylam Pharmaceuticals Inc Composições e métodos para silenciamento da expressão de scn9a
US20230183707A1 (en) 2020-05-21 2023-06-15 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting marc1 gene expression
EP4367237A2 (fr) 2021-07-09 2024-05-15 Alnylam Pharmaceuticals, Inc. Composés bis-arni pour administration au snc
WO2024059165A1 (fr) 2022-09-15 2024-03-21 Alnylam Pharmaceuticals, Inc. Compositions d'arni de 17b-hydroxystéroïde déshydrogénase de type 13 (hsd17b13) et leurs procédés d'utilisation

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4394448A (en) * 1978-02-24 1983-07-19 Szoka Jr Francis C Method of inserting DNA into living cells
US4235871A (en) * 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4241046A (en) * 1978-11-30 1980-12-23 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4713324A (en) * 1983-09-01 1987-12-15 Technicon Instruments Corporation Inverted latency specific binding assay
US4789633A (en) * 1984-04-19 1988-12-06 University Of Tennessee Research Corporation Fused liposome and acid induced method for liposome fusion
US4643988A (en) * 1984-05-15 1987-02-17 Research Corporation Amphipathic peptides
JPS6176414A (ja) * 1984-09-21 1986-04-18 Shionogi & Co Ltd リポソーム製剤の製法
US5223263A (en) * 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US4933121A (en) * 1986-12-10 1990-06-12 Ciba Corning Diagnostics Corp. Process for forming liposomes
US5094785A (en) * 1986-12-10 1992-03-10 Ciba Corning Diagnostics Corp. Process for stabilizing liposomes
JPS63182029A (ja) * 1987-01-22 1988-07-27 Agency Of Ind Science & Technol リポソ−ム
US5049392A (en) * 1989-01-18 1991-09-17 The Liposome Company, Inc. Osmotically dependent vesicles
US5227170A (en) * 1989-06-22 1993-07-13 Vestar, Inc. Encapsulation process
JP2958076B2 (ja) * 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5858784A (en) * 1991-12-17 1999-01-12 The Regents Of The University Of California Expression of cloned genes in the lung by aerosol- and liposome-based delivery
EP0692972B2 (fr) * 1993-04-02 2012-03-21 AntiCancer, Inc. Procede permettant l'apport aux follicules pileux de compositions profitables

Also Published As

Publication number Publication date
EP0835099A1 (fr) 1998-04-15
DE69633669D1 (de) 2004-11-25
AU700376B2 (en) 1999-01-07
CA2223637A1 (fr) 1996-12-19
ATE279912T1 (de) 2004-11-15
WO1996040062A1 (fr) 1996-12-19
AU5976896A (en) 1996-12-30
EP0835099A4 (fr) 2000-11-08
DE69633669T2 (de) 2005-10-20
US5756122A (en) 1998-05-26

Similar Documents

Publication Publication Date Title
EP0835099B1 (fr) Procede de transfection de cellules a l'aide d'acides nucleiques encapsules dans des liposomes
Dodds et al. Lipofection of cultured mouse muscle cells: a direct comparison of Lipofectamine and DOSPER
US5783566A (en) Method for increasing or decreasing transfection efficiency
EP1096921B1 (fr) Complexes d'acides nucleiques encapsules dans des liposomes
EP0752997B1 (fr) Nouveaux phospholipides cationiques destines a la transfection
EP1156783B1 (fr) Encapsulation de complexes bioactifs dans des liposomes
CA2196780C (fr) Systeme d'administration liposomique comprenant des lipopolyamines cationiques et des lipides neutres pour l'administration d'agents biologiquements actifs
Maurer et al. Lipid-based systems for the intracellular delivery of genetic drugs
Monck et al. Stabilized plasmid–lipid particles: pharmacokinetics and plasmid delivery to distal tumors following intravenous injection
AU3381599A (en) Cationic lipid formulation delivering nucleic acid to peritoneal tumors
MXPA05010499A (es) Particulas lipidicas que tienen un revestimiento lipidico asimetrico y metodo de preparacion de las mismas.
KOSHIZAKA et al. Novel liposomes for efficient transfection of β-galactosidase gene into COS-1 cells
Ochiya et al. Evaluation of cationic liposome suitable for gene transfer into pregnant animals
Li et al. Delivery of a PCR amplified DNA fragment into cells: a model for using synthetic genes for gene therapy
KR20000070914A (ko) 안정화된 양이온 형질감염제(들)/핵산 입자의 제형
Zhou et al. Improved encapsulation of DNA in pH-sensitive liposomes for transfection
Boulikas et al. Histones, protamine, and polylysine but not poly (E: K) enhance transfection efficiency
JP2002508956A (ja) 遺伝子送達のための方法および組成物
KR19980067138A (ko) 유전자 또는 생물학적 활성 약물을 세포내로 효과적으로 전달하는 지방 유제 및 그것의 제조방법
US7732420B2 (en) Combinations of transfection lipids exhibiting increased transfection efficiencies
CA2452088A1 (fr) Compositions et methodes d'administration intracellulaire
WO1997034483A1 (fr) Procedes pour augmenter ou diminuer l'efficacite d'une transfection
JP3908776B2 (ja) 細胞への遺伝子導入用組成物
CN118178323A (zh) 类脂化合物、响应增强型类脂化合物、脂质载体、组合物和应用
Wasan et al. 15 Targeted Gene Transfer: A Practical Guide Based on Experience with Lipid-Based Plasmid Delivery Systems

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980105

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

A4 Supplementary search report drawn up and despatched

Effective date: 20000927

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20030804

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: IT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRE;WARNING: LAPSES OF ITALIAN PATENTS WITH EFFECTIVE DATE BEFORE 2007 MAY HAVE OCCURRED AT ANY TIME BEFORE 2007. THE CORRECT EFFECTIVE DATE MAY BE DIFFERENT FROM THE ONE RECORDED.SCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20041020

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69633669

Country of ref document: DE

Date of ref document: 20041125

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050120

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050120

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20050120

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050606

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050606

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050630

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20050721

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20050320

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20090617

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20090625

Year of fee payment: 14

Ref country code: DE

Payment date: 20090629

Year of fee payment: 14

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20100606

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20110228

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20110101

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100630

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100606